Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

New England Journal of Medicine

Volumn 371, Issue 11, 2014, Pages 1005-1015

  Roberts, K G ^a   Li, Y ^b,e   Payne Turner, D ^a   Harvey, R C ^a   Yang, Y L ^a   Pei, D ^c   McCastlain, K ^a   Ding, L ^e,g,h   Lu, C ^e,g,h   Song, G ^a   Ma, J ^a   Becksfort, J ^b   Rusch, M ^b,e   Chen, S C ^a,c   Easton, J ^e   Cheng, J ^e   Boggs, K ^e   Santiago Morales, N ^a   Iacobucci, I ^a   Fulton, R S ^e,g,h   Wen, J ^a   Valentine, M ^f   Cheng, C ^b   Paugh, S W ^c   Devidas, M ^j,ae   Chen, I M ^ae   Reshmi, S ^k,ae   Smith, A ^k   Hedlund, E ^b,e   Gupta, P ^b,e   Nagahawatte, P ^b,e   Wu, G ^b,e   Chen, X ^b,e   Yergeau, D ^e   Vadodaria, B ^e   Mulder, H ^e   Winick, N J ⁿ   Larsen, E C ^s   Carroll, W L ^t,ae   Heerema, N A ^l   Carroll, A J ^v   Grayson, G ^o   Tasian, S K ^w   Moore, A S ^x   Keller, F ^aa   Frei Jones, M ^p   Whitlock, J A ^ab   Raetz, E A ^ac   White, D L ^y   Hughes, T P ^z   Guidry Auvil, J M ^ad,ae   Smith, M A ^ae,af   Marcucci, G ^m   Bloomfield, C D ^m   Mrozek K ^m   Kohlschmidt, J ^m,af   Stock, W ^ag   Kornblau, S M ^q   Konopleva, M ^r   Paietta, E ^u   Pui, C H ^d   Jeha, S ^d   Relling, M V ^c,e,ae   Evans, W E ^c,e   Gerhard, D S ^ad,ae   Gastier Foster, J M ^k,ae   Mardis, E ^e,g,h,i   Wilson, R K ^e,g,h,i   Loh, M L ^ae,ah   Downing, J R ^a,e,ae   Hunger, S P ^ae,ai   Willman, C L ^a,ae   Zhang, J ^b,e,ae   Mullighan, C G ^a,e,ae   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Departments of Computational Biology and Bioinformatics   (United States)

^c Division of Biostatistics   (United States)

^d Departments of Pharmaceutical Sciences   (United States)

^e Departments of Oncology   (United States)

^f Departments of Pediatric Cancer Genome Project   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j USA   (United States)

^k UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^l THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^m THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁿ OHIO STATE UNIVERSITY   (United States)

^o UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^p TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^q UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s Maine Children's Cancer Program   (United States)

^t NEW YORK UNIVERSITY   (United States)

^u ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^v UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^w CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^x ROYAL CHILDREN'S HOSPITAL   (Australia)

^y SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^z CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^aa HOSPITAL FOR SICK CHILDREN   (Canada)

^ab UNIVERSITY OF UTAH   (United States)

^ac Office of Cancer Genomics   (United States)

^ad Cancer Therapy Evaluation Program   (United States)

^ae NATIONAL CANCER INSTITUTE   (United States)

^af MAYO CLINIC   (United States)

^ag UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^ah UNIVERSITY OF CALIFORNIA   (United States)

^ai UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; DASATINIB; INTERLEUKIN 7 RECEPTOR; JANUS KINASE 2; PROTEIN KINASE TYK2; RUXOLITINIB; STAT5 PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; CRLF2 PROTEIN, HUMAN; CYTOKINE RECEPTOR; DNA; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ABL1 GENE; ABL2 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CRLF2 GENE; CSF1R GENE; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EPOR GENE; EVENT FREE SURVIVAL; FEMALE; FLT3 GENE; GENE; GENE EXPRESSION PROFILING; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IL7R GENE; IN VITRO STUDY; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; NTRK3 GENE; OVERALL SURVIVAL; PDGFRB GENE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME LIKE ACUTE LYMPHOBLASTIC LEUKEMIA; PRE B LYMPHOCYTE; PROTEIN PHOSPHORYLATION; PTK2B GENE; RISK FACTOR; SH2B3 GENE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TSLP GENE; TUMOR XENOGRAFT; TYK2 GENE; ANIMAL; DNA MICROARRAY; DRUG ANTAGONISM; GENETICS; HUMAN GENOME; INFANT; METABOLISM; MORTALITY; MOUSE; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; XENOGRAFT; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; CHILD; CHILD, PRESCHOOL; DNA, NEOPLASM; FEMALE; GENOME, HUMAN; HETEROGRAFTS; HUMANS; INFANT; MALE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHILADELPHIA CHROMOSOME; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84907080295     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1403088     Document Type: Article

References (39)

1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381: 1943-55.
2. Mullighan CG. Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol 2013; 50: 314-24.
3. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program2010; 2010: 21-9.
4. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-80.
5. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-34.
6. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-4.
7. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013; 122: 2622-9.
8. Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood 2013; 121: 485-8.
9. Kiyokawa N, Iijima K, Yoshihara H, et al. An analysis of Ph-like ALL in Japanese patients. Presented at the American Society of Hematology Annual Meeting, New Orleans, December 7-10, 2013. abstract 352.
10. Te Kronnie G, Silvestri D, Vendramini E, et al. Philadelphia-like signature in childhood acute lymphoblastic leukemia: the AEIOP experience. Presented at the American Society of Hematology Annual Meeting, New Orleans, December 7-10, 2013. abstract 353.
11. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153-66.
12. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 2013; 31(25): e413-e416.
13. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 2013; 98(11): e146-e148.
14. Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 2013; 45: 1226-31.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
17. Cox DR. Regression models and lifetables. J R Stat Soc Series B Stat Methodol 1972; 34: 187-220.
18. R Development Core Team. R: A language and environment for statistical computing. 2009 (http://www .R-project .org).
19. Ernst T, Score J, Deininger M, et al. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br J Haematol 2011; 153: 43-6.
20. Soler G, Radford-Weiss I, Ben-Abdelali R, et al. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9; 10)(q34; q22.3) translocation. Leukemia 2008; 22: 1278-80.
21. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009; 114: 2688-98.
22. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome- associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243-6.
23. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-12.
24. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from a t(5; 9) (q14.1; p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008; 47: 884-9.
25. Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998; 58: 5046-8.
26. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6- NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184-7.
27. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-76.
28. Alessandri AJ, Knezevich SR, Mathers JA, Schultz KR, Sorensen PH. Absence of t(12; 15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias. Med Pediatr Oncol 2001; 37: 415-6.
29. Eguchi M, Eguchi-Ishimae M. Absence of t(12; 15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias. Med Pediatr Oncol 2001; 37: 417.
30. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2006; 103: 6688-93.
31. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev 2007; 21: 2283-7.
32. Taipale M, Krykbaeva I, Whitesell L, et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol 2013; 31: 630-7.
33. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosomepositive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27: 5175-81.
34. Harvey RC, Kang H, Roberts KG, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-Like ("Ph-like" or "BCR-ABL1-Like") signature for therapeutic targeting and clinical intervention. Blood 2013; 122: 826.
35. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115: 5312-21.
36. Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012; 120: 3510-8.
37. Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2- rearranged B-precursor acute lymphoblastic leukemia. Blood 2012; 120: 833-42.
38. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 2013; 13: 559-71.
39. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127-32.